Tessellate BIO
Andree Blaukat is an experienced executive in the biopharmaceutical industry, currently serving as CEO of Tessellate BIO and as a Senior Advisor at BGV (BioGeneration Ventures) since November 2022. Prior to these roles, Andree held several senior positions at the Healthcare Business of Merck from May 2007 to October 2022, including Senior Vice President for both Translational Innovation Platforms in Oncology and Immuno-Oncology, and Head of the Oncology Platform. Andree's earlier career included leadership roles at Merck KGaA and academic positions at the University of Heidelberg and the Ludwig Institute for Cancer Research. Educational qualifications include a Dr.-Ing. in Biochemistry from the University of Mainz and Technical University Darmstadt, as well as a Dipl.-Ing. in Chemistry from Technische Universität Darmstadt.
This person is not in any teams
This person is not in any offices
Tessellate BIO
Tessellate BIO discovers and develops novel precision oncology medicines with the mission to turn cancer patients into cancer survivors. A private preclinical stage biotechnology company, Tessellate BIO is redefining Synthetic Lethality by developing drugs that target unexplored or difficult to drug pathways beyond HRD. Headquartered in the Netherlands and with research labs at the Stevenage Bioscience Catalyst, UK, Tessellate BIO is supported by top-tier life science investors BioGeneration Ventures (BGV) and Forbion.